During the past decade, Northeast Regional Epilepsy Group conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 10 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 7 clinical trials were completed. i.e. 70% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Northeast Regional Epilepsy Group" #1 sponsor was "SK Life Science, Inc." with 5 trials, followed by "Eisai Inc." with 3 trials sponsored, "Marinus Pharmaceuticals" with 3 trials sponsored, "Takeda" with 3 trials sponsored and "Longboard Pharmaceuticals" with 3 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Northeast Regional Epilepsy Group" #1 collaborator was "Ovid Therapeutics Inc." with 2 trials as a collaborator, "Novotech Health Holdings Pte. Ltd." with 1 trials as a collaborator, "Pfizer" with 1 trials as a collaborator, "Sunovion" with 1 trials as a collaborator and "UCB Pharma" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Northeast Regional Epilepsy Group" are "Epilepsy" (8 trials), "Dravet Syndrome" (5 trials), "Partial Epilepsy" (5 trials), "Lennox Gastaut Syndrome" (4 trials) and "Developmental and Epileptic Encephalopathy" (2 trials). Many other conditions were trialed in "Northeast Regional Epilepsy Group" in a lesser frequency.

Most popular intervention types in "Northeast Regional Epilepsy Group" are "Drug" (26 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "LP352" (2 trials), "TAK-935" (2 trials), "Xcopri" (2 trials) and "YKP3089" (2 trials). Other intervention names were less common.

The vast majority of trials in "Northeast Regional Epilepsy Group" are 27 trials for "All" genders.

Currently, there are NaN active trials in "Northeast Regional Epilepsy Group". undefined are not yet recruiting, 7 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Northeast Regional Epilepsy Group, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Northeast Regional Epilepsy Group, 4 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".